Can exercise, diet, and counseling beat fatigue in PBC?
NCT ID NCT07161245
First seen Jun 26, 2026 ยท Last updated Jun 26, 2026
Summary
This study tests whether a program combining exercise, nutritional advice, and psychological support can reduce fatigue in people with primary biliary cholangitis (PBC). 64 participants with moderate to severe fatigue will be randomly assigned to either the rehab program or standard care. The goal is to see if this non-drug approach improves fatigue, quality of life, and cognitive symptoms.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- multimodal rehabilitation program (exercise, nutritional counseling, psychological support)
- What this could lead to
- If it works, this could offer a non-drug way to reduce fatigue and improve quality of life for people with primary biliary cholangitis.
- What could go wrong
- This is a small, early-phase trial with only 64 participants. The program requires significant commitment, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS (PBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Clinic de Barcelona
RECRUITINGBarcelona, Barcelona, 08036, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common cholesterol drug help manage a rare liver disease?
- One pill may tame both itchy skin and stubborn liver disease
- Can a smartwatch help manage a rare liver disease? stanford study investigates
- Can breathing and meditation ease PBC symptoms? new study says maybe.
- New hope for PBC: experimental drug CS0159 enters Mid-Stage trial
- 3000-Patient study aims to predict PBC outcomes from blood tests